Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip

Vertex Pharmaceuticals (VRTX 0.72%) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to doubt the long-term potential of this stock, this setback is an opportunity to buy the dip for those who are willing to hold onto it for at least a few years. Here's why.This growth prospect just took a heavy hitVertex is best known for its therapies for the rare lung disease cystic fibrosis (CF). They provide the v ...